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Relation of urinary albumin excretion to coronary heart disease
and low renal function: Role of blood pressure.
Background. Previous studies report that urinary albumin
excretion is associated with coronary heart disease (CHD). The
present epidemiologic study investigated if (1) blood pressure
status affects the association of urinary albumin excretion with
CHD; and (2) urinary albumin excretion is associated with low
renal function also.
Methods. The cross-sectional association was analyzed of
overnight urinary albumin excretion with prevalence of CHD
(myocardial infarction and/or ischemia as defined by standard
electrocardiogram) and low renal function (overnight creati-
nine clearance <60 mL/min) in a population sample of 1632
men and women with ages 45 to 64 years. Hypertension, hy-
percholesterolemia, smoking habit, and diabetes mellitus were
included in analyses.
Results. CHD prevalence was in the whole sample 8.2%
(N = 134), in the hypertensive subgroup 11.9% (N = 79),
and in the nonhypertensive subgroup 5.7% (N = 55). For
the association between urinary albumin excretion (logarithm-
transformed due to skewed distribution) and CHD, the multi-
variate logistic coefficient with 95% CI was significant in the
whole sample (+0.79, 95% CI = +0.32/+1.26, P < 0.001) and
in the hypertensive subgroup (+0.97, 95% CI = +0.70/+1.24,
P <0.001), not in the nonhypertensive subgroup (−0.06, 95% CI
= −0.80/+0.68, P = 0.997). Prevalence of low creatinine clear-
ance was in the whole sample 4.0% (N = 66), in the hypertensive
subgroup 4.8% (N = 32), and in the nonhypertensive subgroup
3.5% (N = 34). The logistic coefficient between urinary albumin
excretion and low creatinine clearance was borderline signifi-
cant in the whole sample (+0.56, 95% CI = −0.02/+1.14, P =
0.090), significant in the hypertensive subgroup (+0.73, 95% CI
= +0.04/+1.42, P = 0.044), not significant in the nonhyperten-
sive subgroup (−0.07, 95% CI = −1.25/+1.10, P = 0.913).
Conclusion. Results support the use of urinary albumin ex-
cretion as marker of CHD and slightly reduced renal function
in hypertensives.
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The kidneys excrete into urine a small amount of pro-
teins of which albumin is generally the most abundant
one [1]. Urinary albumin excretion is kept low not only by
the glomerular filter but also by tubular reabsorption [1].
Albumin excretion is not measurable by standard urinal-
ysis unless of substantial increases above normal range
[1, 2]. Above-normal urinary albumin is defined as mi-
croalbuminuria when modest and not detectable by stan-
dard urinalysis, macroalbuminuria when more severe [2].
Microalbuminuria is much more common than macroal-
buminuria in the general population [3]. It is frequent in
persons with diabetes mellitus [2, 4] and/or with major
cardiovascular risk factors such as hypertension, smok-
ing, and hypercholesterolemia [2, 3].
A relation between proteinuria and mortality was hy-
pothesized since 1893 [5]. Epidemiologic research data
indicated that the few persons of the general population
with proteinuria in the macroalbuminuria range are at
high risk of death for cardiovascular diseases [6, 7]. The
relation of proteinuria to cardiovascular events is more
evident and relevant to more individuals of the popula-
tion when analyzed by sensitive measurements of urinary
albumin in the microalbuminuria range as almost unani-
mously shown by clinical [8–12] and epidemiologic data
[13–19]. These previous studies support the conclusion
that urinary albumin excretion predicts cardiovascular
diseases independent of blood pressure although data for
nonhypertensive persons were not separately analyzed in
most studies. An uncertain point is whether or not uri-
nary albumin excretion in the microalbuminuria range is
related to low renal function. Research data on this point
are not consistent in clinical [10, 20, 21] and epidemiologic
studies [22, 23].
The present cross-sectional study aimed to investi-
gate in a population sample of middle-age adults the
association of urinary albumin excretion with coronary
heart disease and low renal function with inclusion of
separate analyses for hypertensive and nonhypertensive
persons.
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METHODS
The Gubbio Study is a population-based investigation
in persons residing within the medieval wall of the town
of Gubbio in central Italy. Previous papers report in-
formation for the Gubbio Study on response rates, re-
sponders and nonresponders, time of examinations, and
similarities for gender and age distribution between the
Gubbio Study population sample and the Italian popu-
lation [24–28]. The present analysis deals with data col-
lected for men and women with ages 45 to 64 years in the
second examination of the study. For person in this age
stratum, study protocol included the collection of morn-
ing blood samples under fasting condition and of timed
overnight urine [3, 28]; the administration of standardized
questionnaires on cardiovascular diseases [29], medical
history, drug or dietary treatment, and smoking habit;
measurements of weight, height, and blood pressure; a
standard 12-lead resting electrocardiogram (ECG) read
by the Minnesota Code [30]. For urine collections, partic-
ipants were given written instructions as follows: urinate
before dinner, discard urine and write down time of the
before-dinner void; write down time of the end of the
dinner; collect accurately all urine throughout the night;
complete urine collection at wake-up with first voided
urine (included); and write down time of the wake-up
void. The average between second and third measure-
ments of blood pressure was used for analysis. Weight
and height were used for calculation of body surface area
(BSA) = 0.007184 × heightcm0.725 × weightkg0.425) [31].
Urinary albumin was measured by immunoturbidimetry
preceded by ultrafiltration to concentrate samples with
albumin concentration <7 lg/mL [3, 28]. Automated pro-
cedures were used for measurements in serum (including
glucose, total cholesterol, and creatinine) and urine (in-
cluding creatinine). Duration of overnight collection was
calculated as the interval from the before-dinner void
to the wake-up void. Urine flow rate was calculated as
urine volume/duration of collection. Urinary creatinine
excretion (mg/min) was calculated as urinary creatinine
concentration (mg/mL) × urine flow rate (mL/min). Cre-
atinine clearance was calculated as the ratio between
overnight urinary creatinine excretion rate and serum
creatinine. Urinary creatinine excretion rate and crea-
tinine clearance were expressed with data normalization
per 1.73 m2 of BSA.
Independent variables
Urinary albumin excretion (lg/min) was calculated as
urinary albumin concentration (lg/mL) × urine flow rate
(mL/min). The urinary albumin/creatinine ratio was not
used as independent variable to avoid the confounding
of creatininuria (i.e., muscle mass) [3, 28, 32–34]. Persons
with systolic pressure ≥140 mm Hg and/or diastolic pres-
sure ≥90 mm Hg and/or antihypertensive drug treatment
were defined as hypertensive [35]. The same definition
was used also in persons with signs of possible renal dys-
function to avoid the confounding due to use in the pop-
ulation of two different cut-off points for hypertension.
Hypercholesterolemia was defined as plasma cholesterol
≥6.20 mmol/L (240 mg/100 mL) and/or regular drug treat-
ment for hypercholesterolemia. Diabetes mellitus was
defined as fasting plasma glucose ≥7.2 mmol/L (130 mg/
100 mL) and/or regular treatment with insulin and/or an-
tidiabetic drugs.
Dependent variables
Myocardial infarction and myocardial ischemia were
used for analyses on coronary heart disease. Myocardial
infarction was diagnosed in the presence of definite ECG
abnormalities (large Q waves, Minnesota Code 1.1; or in-
termediate Q waves plus negative T waves, Minnesota
Code 1.2 plus 5.1 or 5.2) or in the presence of the combi-
nation of ECG abnormalities (Minnesota Code 1.2, 1.3,
5.1, 5.2, 6.1, 6.2, 7.1, 7.2, 7.4, or 8.3) plus definite symptoms
at questionnaire for cardiovascular diseases. In persons
without myocardial infarction, myocardial ischemia (ma-
jor and/or minor) was diagnosed in the presence of ECG
abnormalities (Minnesota Code 4.1, 4.2, 5.1 or 5.2 and/or
1.3, 4.3 or 5.3, respectively). Persons with myocardial in-
farction or ischemia. were defined with coronary heart
disease. Questionnaire data on cerebrovascular diseases
were not used for analyses since <3% of persons reported
symptoms of cerebrovascular diseases. Low creatinine
clearance was the main variable used for analyses on renal
function. Creatinine clearance was defined as low when
<60 mL/min × 1.73 m2 BSA [36]. Equations developed
to estimate glomerular filtration and/or creatinine clear-
ance on the basis of serum creatinine [Cockcroft-Gault,
Modification of Diet in Renal Disease Study (MDRD),
etc.] were not used since they are not validated for use in
the population.
Statistical procedures
Data were analyzed by SPSS for Windows with use of
analysis of variance (ANOVA), logistic and linear regres-
sion analysis (uni- and multivariate), chi-square analysis,
analysis of odds ratio (OR) with 95% CI. Regression co-
efficients and 95% CI were exponentiated for calculation
of odds ratio in logistic analyses. The interaction between
a given variable and the relation of urinary albumin ex-
cretion to dependent variables was analyzed with use of
the variable x urinary albumin excretion product [37].
RESULTS
Descriptive statistics
In the population sample of the Gubbio Study, a total
of 1684 persons were with ages 45 to 64 years at second
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Table 1. Descriptive statistics (mean ± SD or prevalence) for urinary
albumin excretion and other variables in men and women with ages 45
to 64 years
Men Women
Number of persons 715 917
Urinary albumin excretion 16.04 ± 83.94 10.78 ± 35.58
lg/min
Urinary albumin/creatinine ratio 15.17 ± 85.67 14.18 ± 40.84
lg/mg
Age years 54.6 ± 5.6 55.2 ± 5.8
% with regular menses — 25.6
Weight kg 78.6 ± 11.6 68.0 ± 11.9
Height m 1.68 ± 0.06 1.55 ± 0.06
Body surface area m2 1.88 ± 0.15 1.67 ± 0.14
% with hypertension 40.0 41.4
% on antihypertensive drugs 26.0 29.9
% with hypercholesterolemia 37.5 41.0
% of smokers 38.9 25.2
% of ex-smokers 42.5 10.8
% with diabetes mellitus 6.3 4.6
% with myocardial infarction 3.6 1.9
% with myocardial ischemia 5.3 5.8
% with coronary heart disease 9.0 7.6
Urinary creatinine excretion 1.022 ± 0.178 0.803 ± 0.153
mg/min ×1.73 m2
Serum creatinine mg/100 mL 1.056 ± 0.152 0.888 ± 0.125
Creatinine clearance 95.0 ± 21.3 88.6 ± 20.6
mL/min × 1.73 m2
% with creatinine clearance 3.6 4.4
<60 mL/min × 1.73 m2
examination (740 men and 944 women). Fifty-two of the
1684 persons (3.1%) were excluded from analyses due to
missing ECG data. Thus, the cohort for the present study
was made of 1632 persons with ages 45 to 64 years (715
men and 917 women). Table 1 shows descriptive data for
the study cohort. Descriptive statistics for other variables
were similar to previously reported data [3, 28]. Urinary
albumin excretion was higher in men than women and
positively skewed in both genders as reported (skewness
> 20) [3, 28]. In the study cohort, prevalence was 4.2% for
microalbuminuria (urinary albumin excretion 20 to 199
lg/min, N = 40 men and 29 women), 0.6% for macroal-
buminuria (urinary albumin excretion >199 lg/min, N =
6 men and 3 women). Due to skewed distribution, uri-
nary albumin excretion was logarithm-transformed (log)
in regression analyses. Definition of urinary albumin ex-
cretion quartiles was done separately in men and women
to have quartiles with the same gender distribution.
Table 2 shows that urinary albumin excretion quartiles
differed for urinary albumin/creatinine ratio and blood
pressure status.
Urinary albumin excretion and coronary heart disease
In univariate analyses, log urinary albumin excretion
rate was related to coronary heart disease in men and
women (logistic regression coefficient = +1.024 and
+0.977, P < 0.006). Table 3 shows that coronary heart
disease prevalence was progressively higher along uri-
nary albumin excretion quartiles. In analyses for men and
women combined, coronary heart disease prevalence in
quartile 4 was 1.96-time (95% CI = 1.36/2.84) higher com-
pared to quartiles 1–3 combined, 2.29-time (95% CI =
1.38/3.79) higher compared to quartile 1. Findings were
similar in separate analyses for myocardial infarction
(men and women combined, quartile 4 compared to quar-
tile 1, prevalence = 4.2% and 2.2%, OR = 1.98, 95% CI =
0.85/4.38) and myocardial ischemia (prevalence = 8.3%
and 3.7%, OR = 2.38, 95% CI = 1.28/4.44). In compar-
ison to persons with urinary albumin excretion <20 lg/
min (without macroalbuminuria and microalbuminuria),
coronary heart disease prevalence was 3.44-time (95%
CI = 1.89/6.29) higher for persons with microalbumin-
uria (prevalence = 21.7% and 7.5%), 6.20-time (95% CI
= 1.53/25.10) higher for persons with macroalbuminuria
(prevalence = 33.3% and 7.5%).
The relation of log urinary albumin excretion rate to
coronary heart disease was significant also in multivariate
analyses with control for gender, age, hypertension, hy-
percholesterolemia, smoking status, and diabetes (men
and women combined, logistic regression coefficient =
0.791, P < 0.001, 95% CI = 0.32/1.26). Coefficients were
similar with exclusion of persons with diabetes mellitus
(0.752, P = 0.003) or with macroalbuminuria (0.831, P =
0.005).
Interaction of blood pressure status. The interaction of
blood pressure status with the relation between urinary
albumin excretion and coronary heart disease was ana-
lyzed by a multivariate logistic model with use of coronary
heart disease prevalence as dependent variable and with
inclusion, among independent variables (log urinary al-
bumin excretion, gender, age, hypertension, hypercholes-
terolemia, smoking status, and diabetes) of an additional
variable calculated as the product of log urinary albumin
excretion × hypertension (yes/no = 1/0) [37]. The coef-
ficient of the additional variable was significant (+0.639,
P < 0.001). Findings were similar when the additional
variable was calculated as the product log urinary albu-
min excretion × systolic pressure (+0.015, P < 0.001) or
diastolic pressure (+0.021, P = 0.023).
Separate analyses for hypertensive and nonhyperten-
sive subgroups supported the interaction of blood pres-
sure status with the relation between urinary albumin
excretion and coronary heart disease. Log urinary albu-
min excretion was related to coronary heart disease in the
hypertensive subgroup (men and women combined, uni-
variate logistic regression coefficient =+1.053, P < 0.001,
95% CI = +0.84/+1.27), not in the nonhypertensive
subgroup (+0.119, P = 0.801, 95% CI = −0.55/+0.79).
Findings were similar with control for other variables
(gender, age, hypercholesterolemia, smoking status, and
diabetes [i.e., significant relation in the hypertensive sub-
group (men and women combined, multivariate logis-
tic regression coefficient = +0.969, P < 0.001, 95%
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Table 2. Urinary albumin excretion and selected variables in gender-controlled quartiles of urinary albumin excretion, men and women
combined
Quartile
1 2 3 4
Urinary albumin excretion lg/min
Men <4.11 4.11–8.62 8.63–14.07 >14.07
Women <4.26 4.26–7.57 7.58–12.30 >12.30 P valuea
Number of persons men/women 179/229 178/230 179/229 179/229 NS
Urinary creatinine excretion mg/minb 0.923 0.900 0.883 0.901 NS
Urinary albumin/creatinine ratio lg/mg 3.4 6.7 12.6 36.0 <0.001
Systolic pressure mm Hg 128.1 128.7 126.3 138.0 <0.001
Diastolic pressure mm Hg 77.6 77.8 77.0 82.3 <0.001
Pulse pressure mm Hg 50.5 50.9 49.4 55.7 <0.001
% on antihypertensive drug 24.0 32.8 19.9 36.0 <0.001
aBy chi-square analysis or analysis of variance (ANOVA); bper 1.73 m2 of body surface area (BSA).
Table 3. Nonadjusted percent prevalence of coronary heart disease and low creatinine clearance by quartile of urinary albumin excretiona
Quartile
1 2 3 4
Urinary albumin excretion median lg/min 2.97 5.50 10.67 16.13
% with coronary heart disease P valueb for contrast P valueb for linearity
Men and women 5.9 4.6 9.8 12.5 <0.001 <0.001
Men 7.3 3.4 10.7 14.5 0.002 0.002
Women 4.8 5.7 9.2 10.9 0.043 0.005
% with low creatinine clearance
Men and women 2.9 4.2 3.2 5.9 0.133 0.072
Men 3.4 2.8 2.8 5.6 0.441 0.283
Women 2.6 5.2 3.5 6.1 0.244 0.147
aRanges of quartiles as in Table 2; bby chi-square analysis.
Table 4. Nonadjusted percent prevalence of coronary heart disease and low creatinine clearance in hypertensive and nonhypertensive persons by
quartilea of urinary albumin excretion (men and women combined)
Quartile
1 2 3 4
Urinary albumin excretion
Median in hypertensives lg/min 3.13 5.37 10.83 17.40
Median in nonhypertensives lg/min 2.85 5.57 10.60 15.31
Number of hypertensives 141 167 124 234
Number of nonhypertensives 267 241 284 174
P valueb for contrast P valueb for linearity
% with coronary heart disease
Hypertensives 7.8 10.2 9.7 16.7 0.038 0.008
Nonhypertensives 4.9 6.2 5.3 6.4 0.796 0.499
% with low creatinine clearance
Hypertensives 1.4 6.6 3.2 6.4 0.082 0.107
Nonhypertensives 3.7 2.5 3.2 5.2 0.513 0.499
aRanges of quartiles as in Table 2; bby chi-square analysis.
CI = +0.70/+1.24), not significant relation in the non-
hypertensive subgroup (−0.062, P = 0.997, 95% CI =
−0.80/+0.68)]. Table 4 shows coronary heart disease
prevalence in hypertensive and non-hypertensive sub-
groups (men and women combined) by urinary albumin
excretion quartile as defined in Table 2. Prevalence of
coronary heart disease was significantly higher in quar-
tile 4 than quartile 1 within the hypertensive subgroup
(OR = 2.36, 95% CI = 1.17/4.78), not within the nonhy-
pertensive subgroup (OR = 1.44, 95% CI = 0.64/3.25).
Findings were similar in analyses separated by gender,
with control for other variables, and with exclusion of
persons with diabetes mellitus (not shown).
Urinary albumin excretion and renal function
In univariate logistic regression analyses, log urinary al-
bumin excretion was not significantly related to low crea-
tinine clearance. Coefficients were positive in all models,
not significant for men (+0.375, P = 0.455), borderline
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significant for women (+0.780, P = 0.089) and for men
and women combined (+0.562, 95% CI = −0.02/+1.14,
P = 0.090). In univariate linear regression analyses with
serum creatinine or creatinine clearance as dependent
variable (i.e., continuous data), coefficients of log urinary
albumin excretion were positive and not significant with
serum creatinine (not shown, P > 0.3), negative and with
various statistical significance with creatinine clearance
(P = 0.255 in men, P = 0.078 in women, P = 0.044 in men
and women combined).
Table 3 shows low creatinine clearance prevalence by
urinary albumin excretion quartile. A weak trend for
a positive relation was found in analyses for men and
women combined. In these analyses, prevalence of low
creatinine clearance in quartile 4 was 1.76-time (95%
CI = 1.05/2.94) higher than in quartiles 1 to 3 combined,
2.06-time (95% CI = 1.02/4.18) higher than in quartile
1. In comparison to persons with urinary albumin ex-
cretion <20 lg/min, low creatinine clearance prevalence
was 1.95-time (95% CI = 0.76/5.01) higher in persons
with microalbuminuria (prevalence = 7.2% and 3.9%),
3.11-time (95% CI = 0.39/25.29) higher in persons with
macroalbuminuria (prevalence=11.1% and 3.9%). Find-
ings were similar with control for other variables (not
shown).
Interaction of blood pressure status. In multivariate
logistic regression analysis with low creatinine clearance
as dependent variable, the regression coefficient of the
product between log urinary albumin excretion and hy-
pertension was borderline significant (+0.455, P = 0.083).
Findings were similar for the product of log urinary albu-
min excretion × systolic pressure (+0.009, P < 0.091) or
diastolic pressure (+0.008, P = 0.093).
Separate analyses for hypertensive and nonhyper-
tensive subgroups supported the interaction of blood
pressure status with the relation between urinary albu-
min excretion and low creatinine clearance. The logis-
tic coefficient of log urinary albumin excretion to low
creatinine clearance was significant in the hypertensive
subgroup (men and women combined, +0.733, 95% CI =
+0.04/+1.42, P = 0.044), not in the nonhypertensive
subgroup (–0.065, 95% CI = −1.25/+1.10, P = 0.913).
Coefficients were similar in multivariate analyses with
control for gender, age, hypercholesterolemia, smok-
ing status, and diabetes (in the hypertensive subgroup,
+0.738, P = 0.043; in the nonhypertensive subgroup
+0.009, P = 0.988). Findings were similar in linear anal-
yses of log urinary albumin excretion to serum creati-
nine or creatinine clearance (not shown). Table 4 shows
low creatinine clearance prevalence by urinary albumin
excretion quartile in hypertensive and nonhypertensive
subgroups. A weak positive association was found in the
hypertensive subgroup, not in the nonhypertensive sub-
group. Prevalence of low creatinine clearance in quar-
tile 4 compared to quartile 1 was 4.76-time (95% CI =
1.07/21.14) higher in the hypertensive subgroup, 1.40-
time (95% CI = 0.56/3.52) higher in the nonhypertensive
subgroup. Findings were similar in multivariate models
with control for other variables (not shown).
Antihypertensive drug treatment was associated with
lower creatinine clearance (88.4 and 92.2 mL/min ×
1.73 m2 BSA, P < 0.001) and higher serum creatinine
(0.979 and 0.946 mg/100 mL, P = 0.131) within the hyper-
tensive subgroup. Thus, analyses in this subgroup were
repeated with control for antihypertensive drug treat-
ment also. In these additional analyses, the coefficient of
log urinary albumin excretion to low creatinine clearance
was significantly positive both without and with control
for gender, age, hypercholesterolemia, smoking status,
and diabetes (+0.742 and +0.728, respectively, P < 0.05).
With control for these variables and antihypertensive
drug treatment, prevalence of low creatinine clearance
within the hypertensive subgroup was 5.33-time (95%
CI = 1.17/24.63) higher in quartile 4 than quartile 1 of
urinary albumin excretion.
DISCUSSION
This epidemiologic study reported data on the associ-
ation of urinary albumin excretion with coronary heart
disease or low creatinine clearance in a population sam-
ple of middle-age adults. Study results confirmed the pre-
viously reported association between urinary albumin
excretion and coronary heart disease in the general pop-
ulation [15, 16]. A novel observation was that the as-
sociation present in the general population was actually
explained only by the subgroup of hypertensive persons.
Different statistical procedures indicated an interaction
between blood pressure status and the association of uri-
nary albumin excretion with coronary heart disease, an
association which was strong and significant in hyperten-
sive persons, weak and not significant in non-hypertensive
persons. For renal function, the study reported the first
population-based data on the association between uri-
nary albumin excretion and low creatinine clearance. As
for coronary heart disease, findings for renal function
were affected by blood pressure status. In fact, the asso-
ciation between urinary albumin excretion and low crea-
tinine clearance was present in hypertensive persons and
absent in nonhypertensive persons. The association of
urinary albumin excretion with low creatinine clearance
in hypertensives was independent also of reported use of
antihypertensive drug(s) which, per se, was a significant
correlate of renal function. Study results suggest that the
association of urinary albumin excretion with coronary
heart disease and low creatinine clearance in hyperten-
sives was continuous and graded over the range of urinary
albumin excretion. The difference in the prevalence of
these two disorders was in fact progressively greater when
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comparisons were made for persons in quartile 4 (uri-
nary albumin excretion >14.07 lg/min in men, >12.30 lg/
min in women), for persons with microalbuminuria (uri-
nary albumin excretion 20 to 199 lg/min), and for per-
sons with macroalbuminuria (urinary albumin excretion
>199 lg/min).
Findings in the present study likely represent an under-
estimate of the true strength of the relationships present
in the population between urinary albumin excretion and
coronary heart disease or low creatinine clearance. A
likely cause of regression dilution bias was the use of a
single measurement of urinary albumin excretion with-
out urinalysis [2, 4]. Additional causes of bias for anal-
yses on renal function could be the use of creatinine
clearance, which overestimates glomerular filtration in
persons with kidney disease [1, 38]. Also, creatinine clear-
ance measurements are affected by daily variability in
urinary creatinine [1, 39]. The gender-controlled quartiles
of urinary albumin excretion differed also for urinary al-
bumin/creatinine ratio in the presence of similar urinary
creatinine excretion. Thus, the confounding could be ex-
cluded of differences in urine collection completeness.
Findings in analyses for the nonhypertensive subgroup
could be affected by the low number of persons with coro-
nary heart disease, hence by low statistical power. Thus,
the possibility cannot be excluded that a relation exists
between urinary albumin excretion and coronary heart
disease also in nonhypertensive persons, yet much weaker
than in hypertensives. A high preexamination mortality
among nonhypertensive persons with high urinary albu-
min excretion (i.e., a survival bias) could theoretically ex-
plain the lack of significant cross-sectional findings in the
nonhypertensive subgroup. Such a possibility appears un-
likely since longitudinal data in the Gubbio cohort show
that fatal coronary heart disease is rare in nonhyperten-
sive persons [40].
Mechanisms underlying the association between uri-
nary albumin excretion and coronary heart disease are
not yet defined [41]. Acute myocardial infarction in-
creases the urinary excretion of albumin and other
protein [42–45]. Thus, the association between urinary
albumin excretion and coronary heart disease could re-
flect urinary albumin changes secondary to myocardial
infarction. Two observations are against this interpreta-
tion. First, the infarction-induced increase in urinary al-
bumin excretion is transient and lasting only few days
[42–45]. Second, findings in the present study were simi-
lar for the association of urinary albumin excretion with
myocardial ischemia and myocardial infarction. Mecha-
nisms are similarly uncertain for the association with low
renal function. It is also unknown whether low renal func-
tion represents or not another aspect of vascular damage
[46]. A slight increase in urinary albumin excretion is rea-
sonably a marker rather than a determinant of coronary
and renal damage. The hypothesis can be made that hy-
pertension is a key factor in damage indicated by high
urinary albumin excretion on the basis of no association
of urinary albumin excretion in nonhypertensive persons.
Other possibilities cannot be excluded.
The lack of significant association between urinary al-
bumin excretion and coronary heart disease in the non-
hypertensive subgroup is not in contrast with previous
observations. Actually, the previous observations were
on microalbuminuria in nonhypertensive persons for the
combination of microalbuminuria with hyperinsulinemia
(not microalbuminuria alone) [14], or for samples in-
cluding persons with measured blood pressure above the
current cutoff points for definition of hypertension [17],
or not significant in multivariate analyses with control
for other variables [18]. For the relation of urinary al-
bumin to creatinine clearance, the finding of an inverse
association in hypertensives is not in contrast with data
reported by Pinto-Sietsma et al [23] in a large population-
based cohort. Results of that study suggest a similarly
inverse association after exclusion of persons with low-
normal urinary albumin, persons who are most often non-
hypertensive due to the relation between blood pressure
and urinary albumin. The observation that antihyperten-
sive drug treatment was per se associated with low renal
function in the present population sample is in keeping
with previous data [47]. It could reflect the combination
of two effects (i.e., changes in renal function secondary
to antihypertensive drugs [48] and/or frequent drug
treatment among severe hypertensives with low renal
function).
Study results have also practical implications. On one
hand, the data limit the importance of urinary albumin
excretion as marker of cardiovascular risk because of no
association in nonhypertensive persons. On the other
hand, the high prevalence of coronary heart disease
among hypertensives with high urinary albumin excretion
underlines the usefulness of urinary albumin excretion
for detection of individuals with or at risk of coronary
heart disease in this subgroup of the population. In
the Gubbio population sample, about one out of seven
hypertensives was with coronary heart disease when
urinary albumin excretion was above the gender-specific
median, a prevalence which was progressively higher with
increasing urinary albumin excretion. Such a strong cross-
sectional association could explain, at least in part, the
predictive power of urinary albumin excretion for inci-
dent cardiovascular events since the presence of coronary
heart disease is per se a strong predictor of major cardio-
vascular events [35]. Possible implications for prevention
of renal disease need further studies in large series of
untreated hypertensives. Moreover, longitudinal studies
are needed to assess whether the mild renal dysfunction
associated with high urinary albumin excretion implies
only the development of more severe albuminuria [21]
or also of progressive renal disease [36].
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CONCLUSION
The study deals with a cross-sectional analysis on the
association of urinary albumin excretion with indices of
coronary heart disease and renal function in a population-
based sample of middle-aged adults. The study reports
two novel findings. First, the association of urinary albu-
min excretion with coronary heart disease is present only
in hypertensive persons. Second, there is a weak associ-
ation between urinary albumin excretion and low renal
function. Such an association, as for coronary heart dis-
ease, is limited to the subgroup of hypertensive persons.
Thus, urinary albumin excretion appears a useful marker
of coronary hear disease and/or low renal function limit-
edly to hypertensive persons.
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